Background: Androgen deprivation therapy (ADT), a standard treatment for prostate cancer (PC), causes many physical side effects. In particular, it causes metabolic changes such as fasting glucose abnormalities or accumulation of body fat, and…
Continue Reading
Avenda Health’s AI tool, Unfold AI, for mapping prostate cancer, received a Category III CPT code for 2024 from the AMA. The code, X237T, facilitates precise cancer localization and treatment planning through an AI-generated…
Continue Reading
Philips and Quibim have teamed up to develop AI-enhanced MR imaging and reporting solutions for prostate exams. This partnership aims to improve prostate cancer care efficiency and accuracy, providing an alternative to traditional PSA…
Continue Reading
A Corewell Health study suggests that men with longer prostatic urethras face a higher risk of urinary side effects after prostate cancer radiation therapy. By utilizing a novel MRI metric, researchers found that for…
Continue Reading
Blue Earth Diagnostics, a leading provider of PET radiopharmaceuticals, is set to present findings on POSLUMA (flotufolastat F 18) injection at the ASTRO 2023 Annual Meeting. POSLUMA aids in PET scans to detect prostate-specific…
Continue Reading
Prostate Cancer Research (PCR) has received sponsorship to support its first of its kind prostate cancer patient data platform and virtual registry.The project, which is supported by IQVIA and sponsored by Bayer and Advanced…
Continue Reading
MRI scans combined with PSA density in prostate cancer screening, pioneered by a UCL-led study, identified cases missed by PSA tests alone. The REIMAGINE study revealed that 15 participants with significant cancer had ‘low’…
Continue Reading
Paige partners with Ohio State Wexner Medical Center to assess AI’s role in precise prostate cancer diagnosis in community hospitals. The collaboration employs the FDA-approved Paige Prostate Detect AI tool to gauge diagnostic accuracy,…
Continue Reading
By Shania Kennedy
June 22, 2023 – Researchers evaluating an artificial intelligence (AI) model’s ability to estimate prostate cancer extent and define focal treatment margins for tumors demonstrated that the model outperformed conventional methods, according to…
Continue Reading
Blue Earth Diagnostics and PETNET Solutions, a Siemens Healthineers Company, have announced the availability of POSLUMA (Flotufolastat F 18) Injection for PET Imaging of Prostate Cancer in the United States. POSLUMA, an optimized PET…
Continue Reading
